Почетна › Немалоклетни карцином плућа › Masachuset › Boston
Kliničke studije za Немалоклетни карцином плућа u gradu Boston, MA
87 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Boston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Тражи се учесникФаза 2/3
- Dana-Farber Cancer Institute, Boston
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Тражи се учесникФаза 3
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital - Neurology, Boston
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Тражи се учесникФаза 3
- Research Site, Boston
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Тражи се учесникФаза 3
- Massachusetts General Hospital ( Site 0136), Boston
- Dana Farber Cancer Hospital ( Site 0155), Boston
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- Dana-Farber Cancer Institute, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital (MG), Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Тражи се учесникФаза 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- Massachusetts General Hospital, Boston
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Тражи се учесникФаза 3
- Local Institution - 0603, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Boston Medical Center, Boston
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Тражи се учесникФаза 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- Boston Medical Center, Boston
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute (DFCI), Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Тражи се учесникФаза 1
- Dana Farber Cancer Institute, Boston
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Тражи се учесникФаза 3
- Dana-Farber Cancer Institute, Boston
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Тражи се учесникФаза 2/3
- Dana-Farber Cancer Institute, Boston
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Тражи се учесникФаза 1
- Dana Farber Cancer Institute, Boston
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Тражи се учесникФаза 3
- Research Site, Boston
- Research Site, Boston
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute /ID# 278417, Boston
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Тражи се учесникФаза 3
- Dana-Farber Cancer Institute, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Тражи се учесникФаза 1
- Research Site, Boston
- Research Site, Boston
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Dana-Farber Cancer Institute, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Тражи се учесник
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
Тражи се учесникФаза 1
- Massachusetts General Brigham, Boston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- Research Site, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Тражи се учесникОпсервациона студија
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- и још 1
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
DNA Analysis of Blood and Tissue From Patients With Lung Cancer
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Тражи се учесникФаза 1
- Exelixis Clinical Site #7, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Тражи се учесникФаза 3
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1
- PHN-012-001 Site, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Тражи се учесникФаза 1
- Research Site, Boston
- Research Site, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Тражи се учесникФаза 1/2
- Tufts Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Тражи се учесникФаза 1/2
- Massachusetts General Hospital - Main Campus, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Тражи се учесникФаза 3
- Clinical Study Site, Boston
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Тражи се учесникФаза 2
- Dana-Farber Cancer Institute, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Тражи се учесникФаза 2
- Massachusetts General Hospital (Data Collection Only), Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
Тражи се учесник
- Brigham and Women's Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Massachusetts General Hospital Cancer Center, Boston
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
Тражи се учесник
- Dana-Farber Cancer Institute, Boston
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center, Boston
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Тражи се учесникФаза 1
- Dana Farber Cancer Institute, Boston
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Тражи се учесникФаза 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- и још 2
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Тражи се учесникФаза 1
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Research Site, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Тражи се учесникФаза 1/2
- Massachusetts General Hospital,, Boston
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Тражи се учесникФаза 3
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Тражи се учесникФаза 1/2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1
- Dana Farber Cancer Institute, Boston
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Тражи се учесникФаза 1
- Massachusetts General Hospital, Boston
Patient-centered, Optimal Integration of Survivorship and Palliative Care
Тражи се учесник
- Massachusetts General Hospital, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Studije za Немалоклетни карцином плућа u drugim gradovima
- Houston, TX143 студија
- New York City, NY123 студија
- Arlington, VA111 студија
- Nashville, TN97 студија
- Los Angeles, CA92 студија
- St. Louis, MO68 студија
- Baltimore, MD60 студија
- San Antonio, TX60 студија
- Chicago, IL59 студија
- Columbus, OH57 студија
- Seattle, WA55 студија
- Washington, DC55 студија
Ostale studije u gradu Boston
- Рак дојке110 студија
- Рак (све врсте)90 студија
- Рак плућа63 студија
- Колоректални карцином62 студија
- Рак јајника62 студија
- Метастатски карцином61 студија
- Рак простате56 студија
- Карцином ендометријума51 студија
- Депресија50 студија
- Затајење срца46 студија
- Многи мијелом45 студија
- Akutna mijeloidna leukemija44 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.